Find comprehensive SWOT and PESTLE research reports across industries globally

Holistic Analysis Customized Solutions Top Quality

Please Enter Correct Data! X
Thanks for downloading our report! X
Check your email for the requested analysis report.
Be sure to place on your approved senders list to prevent emails from going into spam.
Thanks for downloading our sample report! X
Check your email for the requested sample analysis report.
You can also download it here.
Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Great quality, Affordable pricing X

As a leading strategy research portal we invest deep to produce imperial quality reports that can help corporate professionals, academicians and students take their research forward and set a benchmark for high standard business research. The cost for reports has been kept minimal to just cover our operational and maintenance costs although the mission is not to reap monetary benefits. We look forward to your support.

Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Bristol-Myers Squibb (BMS) SWOT & PESTLE Analysis

ID : 52385653 | Apr 2018

COMPANY PROFILE - Bristol-Myers Squibb (BMS)

Business Sector : Pharmaceuticals

Operating Geography : United States, Global

About Bristol-Myers Squibb (BMS) : Bristol-Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City. Their products are sold worldwide (U.S. being the biggest market, contributing 55% to overall revenue) and manufactured in the U.S., Puerto Rico and in five foreign countries. BMS was formed by the 1989 merger of Squibb (founded in 1858 in Brooklyn) and Bristol-Myers (founded in 1887 in Clinton, New York). Their Products can be categorized in the following major therapeutic classes: oncology; cardiovascular; immune-science; and virology, including HIV infection.

Its mission statement states ‘At Bristol-Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.’

Bristol-Myers Squibb (BMS) Revenue : $20.77 billion – FY ending Dec 2017

$19.43 billion – FY ending Dec 2016

Competitive Analysis of Bristol-Myers Squibb (BMS)

The SWOT analysis for Bristol-Myers Squibb is presented below:
1. Innovation – New Product Development
2. Strong focus on R&D
3. Strong brand portfolio
4. High credit rating, low borrowing cost
5. Complimentary alliances for vertical integration
6. Strategic investment in sales & marketing
1. Revenue dependence on few prioritized brands
2. Weak presence in biologics segment
1. Growing cancer immunotherapy market
2. Increasing globalization in Pharma industry, opening of new markets through trade agreements
3. Leverage advance digital technologies to transform healthcare
1. Increasing competition from generic drugs manufacturers
2. Changes in U.S. or foreign laws and regulations
3. Adverse changes in U.S., global, regional or local economic conditions

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."
Safe and secure payments

Detailed SWOT Analysis of Bristol-Myers Squibb (BMS)



This section is available only in the 'Complete Report' on purchase.


1. Revenue dependence on few prioritized brands: If we analyze product wise sales of BMS we can see that top selling prioritized drugs (namely Opdivo, Eliquis, Orencia, Sprycel,Yervoy and Baraclude) constituted around 80% of revenue in year 2017. Revenue share of products shows that the company depends heavily on its key products and lacks differentiation in product portfolio.

2. Weak presence in biologics segment: Biologics have revolutionized the treatment of many serious and chronic illnesses and many companies are investing heavily considering the future potential including BMS, however if we look at the top 10 biologics brand, not a single product is from BMS.


This section is available only in the 'Complete Report' on purchase.


1. Increasing competition from generic drug manufacturers: One of the biggest competitive challenges that BMS face is from generic pharmaceutical manufacturers. Generic manufacturers typically utilize the expired patents of research pharmaceutical companies and thus they are able to keep their R&D investments significantly low and therefore can price their products significantly lower than branded products. Upon the expiration or loss of market exclusivity on a product, BMS can lose the major portion of revenues of that product in a very short period of time.

2. Changes in U.S. or foreign laws and regulations: In many countries determination of pricing and reimbursement for pharmaceutical product is subject to government control. In most EU countries, for example, the government regulates pricing of a new product at launch often through direct price controls, international price comparisons, controlling profits and/or reference pricing. In recent years, Italy, for example, has imposed mandatory price decreases.

3. Adverse changes in U.S., global, regional or local economic conditions: Global economic risks pose significant challenges to a BMS’s growth and profitability and are difficult to mitigate. In 2016, 45% of the total revenue of BMS came from countries other than USA. Given this non-dollar revenue composition, fluctuation in U.S. dollar poses a significant risk to their overall profit. Any major political event (like Brexit) in Europe can negatively impact the overall operations since BMS have a major part of their operations present there, including manufacturing and distribution.

The PESTLE/PESTEL analysis for Bristol-Myers Squibb is presented below:
1. Changes in U.S. or foreign laws and regulations
2. Reduction in government spending on healthcare
1. Fluctuations in currency market
2. Global Economic uncertainty
1. Continued aging of the global population
2. Increase in lifestyle-related diseases
1. Proliferation in digital health technologies
2. Rise in advanced analytics
1. Changes in IP protection laws
2. Laws to reduce circulation of counterfeit drugs
1. Corporate vision aligned with sustainable development to address climate change
* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."
Safe and secure payments

Detailed PESTLE Analysis of Bristol-Myers Squibb (BMS)



1. Changes in U.S. or foreign laws and regulations: BMS could become subject to new government laws and regulations, which could negatively affect their business, operating results and the financial condition. These laws can be healthcare reform initiatives imposing mandatory discounts or fees; changing tax rates; new laws affecting pricing; changes in intellectual property laws; new trade laws affecting imports etc.

2. Reduction in government spending on healthcare: Revenue of any pharma company is largely impacted by the changes in government spending on healthcare since many large medical contracts are executed by governments. But there has been instances of healthcare budget cuts for example The European Federation of Pharmaceutical Industries and Associations (EFPIA) estimates that govt. mandated price cuts and discounts in the GIIPS (Greece, Ireland, Italy, Portugal, and Spain) countries brought down the industry’s revenues by more than $8.8 billion in 2010 and 2011. With GIIPS governments continuing their budget cuts, overall pharma sales are expected to fall by $15.9 billion between year 2011 and 2020.


This section is available only in the 'Complete Report' on purchase.


This section is available only in the 'Complete Report' on purchase.


1. Proliferation in digital health technologies: Digital health technology is creating a paradigm shift in life sciences. Health data captured by wearable devices, mobile health apps, and social media are being used to transform aspects of health care that earlier seemed beyond the purview of such technologies. These technologies are providing an important platform for Pharma companies to strengthen patient engagement programs and collaborate with other stakeholders. A notable example in respect of BMS is that it has announced collaboration with GRYT Health, a connected health start-up. The collaboration which is a digital pilot initiative will focus on advance cancer care through patient-driven insights.

2. Rise in advanced analytics: Advanced analytics represent another side of the technology coin. Whereas the much-hyped “personalized medicine era” has yet to fully take hold, the industry and research communities are clearly moving in that direction and advanced analytics may play a key role. Technology companies are developing in vitro companion diagnostic devices that pharma companies may use to target specific diseases based on patients’ personalized genomic profiles. These devices may also be helpful for data-gathering purposes, and thus may allow drug companies and regulatory bodies to share data. BMS has used Big Data for analysis of data from labs and generate new insights in clinical trials. One notable example is Translational Bioinformatics where BMS teams are using cutting-edge algorithms to sift through massive raw genomics data. Data and analytics has led significant saving of time and resources for BMS and improved the overall efficiency.


This section is available only in the 'Complete Report' on purchase.


This section is available only in the 'Complete Report' on purchase.

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."
Safe and secure payments

Check out analysis of other relevant companies

References used in Bristol-Myers Squibb (BMS) Analysis Report

1. Bristol-Myers Squibb Annual Report 2016:

2. Bristol-Myers Squibb Company Analysis

3. BMS areas of focus

4. Most Innovative Companies

5. Reshaping Bristol-Myers-Squibb

6. BMS list of products

7. Product sales summary

8. Top 10 Biologic Drugs in the United States

9. The top 15 spenders in the global drug R&D business: 2017

10. From vision to decision: Pharma 2020

11. Awards and achievements

12. Cancer immunotherapy market race

13. World Population Prospects: The 2017 Revision; Gloabl Pharma Prospects

14. Environmental Performance

15. Sustainability 2020 Goals

Copyrights and Disclaimer

Bristol-Myers Squibb (BMS) SWOT and PESTLE analysis has been conducted by Sachin Mishra and reviewed by senior analysts from Barakaat Consulting.

Copyright of Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.